ImpriMed, Inc. announced that it will receive $23,292,280.83 in a round of funding on October 12, 2023. The company will issue 8,582,136 series A preferred shares at issue price of $2.2139 per share for a gross proceeds $18,999,990.8904; 112,924 series A-1 preferred shares at issue price of $1.7712 per share for the gross proceeds $200,010.9888; and 2,174,662 series A-2 preferred shares at issue price of $1.8818 per share for the gross proceeds $4,092,278.9516. The shares are convertible and non-redeemable.

The shares will be convertible into common shares at a price of $2.2139; $1.7712; and $1.8818 per share respectively. The round will be raised at post post-money valuation of $47,516,090.